Glox Therapeutics, a precision antibiotic therapy developer based in Glasgow, Scotland, has successfully raised £4.3 million in seed funding. The funding round was led by Boehringer Ingelheim Venture Fund and Scottish Enterprise. With this investment, the company plans to advance its research in developing targeted therapeutics that combat antibiotic-resistant Gram-negative bacteria. Glox Therapeutics also aims to establish laboratories in both Oxford and Glasgow, in addition to expanding its team to accelerate its bacteriocin development program. The company was founded in February 2023 by Prof. Daniel Walker from the University of Glasgow (now at the University of Strathclyde) and Prof. Colin Kleanthous from the University of Oxford. The CEO of Glox Therapeutics, Dr. James Clark, is leading the team's efforts to harness the potential of engineered protein bacteriocins in their antibiotic development.
The precision antibiotics being developed by Glox Therapeutics utilize bacteriocins, which are naturally occurring antimicrobial proteins produced by bacteria.
These novel antimicrobials have shown remarkable potency and specificity, making them effective against Gram-negative pathogens that have already developed antimicrobial resistance (AMR), such as Pseudomonas aeruginosa and Klebsiella pneumoniae. By leveraging the unique properties of bacteriocins, Glox Therapeutics aims to revolutionize the field of antimicrobial therapy and overcome resistance to traditional antibiotics. The company's approach focuses on selectively eradicating target pathogens while preserving the patient's microbiomes, resulting in a more balanced and effective treatment strategy with reduced side-effects.
The successful seed funding round led by Boehringer Ingelheim Venture Fund and Scottish Enterprise will enable Glox Therapeutics to advance its research and development efforts. One of the key plans for the company is the establishment of laboratories in Oxford and Glasgow, which will provide state-of-the-art facilities for their scientific endeavors. Additionally, the funding will support the expansion of Glox Therapeutics' team, allowing them to accelerate their bacteriocin development program. With the backing of experienced investors and a dedicated team, Glox Therapeutics is well-positioned to make significant contributions in the fight against antibiotic-resistant bacteria and improve the effectiveness of antimicrobial therapy.
|Business Name||Glox Therapeutics|
|Founder||Prof. Daniel Walker|
|Founder||Prof. Colin Kleanthous|
|Founder||Dr. James Clark|
|Investor||Boehringer Ingelheim Venture Fund|